EX-99.3 5 ex99_3.htm EX. 99.3 FACT SHEET ex99_3.htm  

PAGE 1- See Graphics
 
Investor Fact Sheet
 
Ticker Symbol: NASDAQ: CEMI
www.chembio.com

Business Summary & Investment Highlights
 
Chembio Diagnostics, Inc., (Chembio), through its wholly-owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care testing (POCT) products. Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create significant new revenue streams that will add to Chembio’s core business of rapid HIV tests.
 
 
·  
Three Consecutive Years of Profitability and Revenue Growth
 
 
·  
Strategy is to create core business of public health and women’s health products to be complemented by OEM and selected out-licensing opportunities.
 
 
·  
Robust pipeline of POCT products for infectious diseases based on Chembio’s patented DPP® technology.
 
 
·  
Products developed on DPP® platform include oral fluid HIV test anticipated to be reviewed by FDA during 2012.   Unique Syphilis tests will be submitted and undergoing US FDA regulatory evaluations in 2012.  Several other products and collaborations in pipeline.
 
 
·  
Unique opportunity to participate in nascent U.S. market for OTC HIV tests with multiple product offerings.
 
 
·  
Five DPP® products approved in Brazil during 2010-11 are anticipated to generate at least $9MM in 2012 revenues as compared with $4.5MM in 2011.
 
 
Selected Financial Information
 
Stock Information
Ticker Symbol: NASDAQ: CEMI
Price 12/31/2012   $4.73
52 Week High   $5.80
52 Week Low $3.10
Outstanding Shares (MM) 8.0
Market Capitalization (MM) $37.8
Fully Diluted (FD) Shares (MM) 8.8
Management Holding-FD (MM): 1.6
Average Daily Vol. (3 Mos) 52,000


Major Beneficial Holders Beneficial Shares Owned (MM)
Lawrence Siebert: 894


 
 
 
 
 

 
     
Balance Sheet Data ($000s)
Sept’12
Dec ‘11
Cash
$3,290
$ 3,011
Accts. Receivable
2,567
2,998
Inventories
3,038
2,300
Other Current Assets
706
682
Total Current Assets
9,601
8,991
Net Fixed Assets
1,335
1,062
Other Assets
5,204
5,432
Total Assets
16,140
15,486
Total Current Liab.
2,761
2,858
Total Other Liab.
95
133
Total Liabilities
2,856
2,991
Total Equity
13,284
12,495
Total Liabilities & Stockholders’ Equity
$16,140
$15,486
     

Selected Comparative Historical Financial Data

 
For the Quarter Ended/ For the Nine Months Ended/For the
Year Ended
  
$(000s)
 
Q3’12
 
Q3’11
 
 
Q3’12
 
Q3’11
2011
 
 2010
  2009
    
Total Revenues
$5,007
$5,921
17,744
13,171
$19,388
 $ 16,705
 $13,834
    
Cost of sales
3,278
3,251
10,112
6,524
    9,998
      8,604
      7,974
    
Gross Profit
1,729
2,670
7,632
6,647
    9,390
     8,101
      5,860
    
 
34.5%
45.1%
43.0%
50.5%
48.4%
     48.5%
42.4%
    
R&D Expense
1,006
1,242
3,364
3,697
    4,878
      2,586
      2,884
    
SG&A Expense
1,208
949
3,522
2,413
    3,424
      2,941
      2,659
    
Operating Income
(485)
479
746
537
   1,088
      2,574
         317
    
Other Inc. (Expense)
(1)
(3)
(2)
(9)
(12)
        (15)
           (8)
    
Net Income  -PreTax
(4860
476
744
528
  1,076
       2,559
         309
    
Inc. Tax(Ben.) Prov.
(193)
-
295
-
 (5,133)
-
-
    
Net Income (Loss)
$(293)
$476
$449
$528
$6,209
        
Net Income(Loss) - per Share
$0.04
$0.06
0.06
.07
$0.10
 $    0.04
 $   0.00
    
Wt. Avg. No. Shares (MM)
8.001
7.913
7.974
7.861
63.328
   62.103
    61.946
    
Working capital
$6,841
$5,281
$6,841
$5,281
6,134
 $  4,560
 $ 1,494
    
Total assets
16,140
10,099
16,140
10,099
15,486
   9,086
   6,315
    
Total liabilities
2,856
3,345
2,856
3,345
2,991
  3,277
      3,227
    
Equity
13,284
6,754
13,284
6,754
12,495
5,809
   3,088
    


 Chembio Diagnostics, Inc.
Investor Relations
 Company Contact
 3661 Horseblock Road
Lippert-Heilshorn & Associates
Susan Norcott
 Medford, NY 11763
Anne-Marie Fields, Vice President
 631-924-1135 x125
 Ph. 631-924-1135
(212) 838-3777
 snorcott@chembio.com
 Fax 631-924-2065
AFields@lhai.com
  
 www.chembio.com
    
 

PAGE 2 – See Graphics

DPP® Technology
Competitive Advantages For POC Testing

• Improved Sensitivity - enabled by more efficient binding method
• Easier Multiplexing - due to even and direct distribution of sample to multiple test lines
• Enhanced Sample Control - as result of independent sample migration path
• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results

Chembio’s Dual Path Platform (DPP®) Patented in 2007  (see graphic)


Chembio’s Lateral Flow Rapid HIV Tests Marketed Exclusively in the USA by Alere North America, Inc.
 
 

 

Senior Management Team
Lawrence A. Siebert, Chairman & CEO, over 25 years of management and financing experience
Richard J. Larkin, CFO, over 25 years of operational and financial experience
Javan Esfandiari, SVP R&D, over 15 years of experience in development of in-vitro point-of- care products

Independent Members of Board of Directors
Katherine Davis - Former Lieutenant Governor and numerous other leadership positions for the State of Indiana; former senior executive of Cummins, Inc. (NYSE:CMI)
Dr. Barbara DeBuono – Former New York Commissioner of Health and Rhode Island Director of Health; other positions in domestic and international medical services
Dr. Peter Kissinger – Has founded and/or led 3 biotechnology and/or biomedical technology companies, including a publicly-traded NASDAQ company
Dr. Gary Meller - Broad experience in medical and information technology and pharmaceutical product development

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostic’s Inc. most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. –Dec. 2012.